Clinical Trial Update: Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

View source ↗

Summary

An observational study in Canadian patients aged 6 years and older examines outcomes of Dupixent (dupilumab) for moderate to severe atopic dermatitis. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Sanofi | Conditions: Moderate to Severe Atopic Dermatitis | Status: ACTIVE_NOT_RECRUITING